San Francisco, CA, USA - Novotech, a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase announced today that it will have the largest ever presence at the J.P.Morgan Healthcare Conference in San Francisco, CA, USA, January 8-11, 2024.
This marks a significant milestone for the company as it has finalized the integration of its acquisitions of EastHORN and CBR International solidifying its position as a leading global CRO for the biotech sector.
The executive team will be participating in the following partnering platforms during the Conference:
- CTIC – January 7, 2024, at the Intercontinental San Francisco
- Biotech Showcase – January 8 -10, 2024, at the San Francisco Hilton
- BIO Partnering – January 8 -11, 2024, at the San Francisco Marriott Marquis
- RESI – January 9, 2024, at the Marines Memorial Club
Schedule a meeting with the team
Novotech offers an integrated and scaleable clinical development approach across more than 25 geographies and is highly regarded for its scientific expertise in key therapeutic areas including:
- Oncology
- Cell & Gene Therapy
- Liver disease
- Infectious diseases and vaccines
- Orphan and rare diseases
Novotech has more than 3,000 employees across 34 office locations in the US, Greater China, South Korea, Australia, New Zealand, and Europe.
The CRO offers biotechs a unique and unparalleled suite of early to late-phase services across the US and Europe, with a foundation in Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials. Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.
Media contact
Toyna Chin
About Novotech Novotech-CRO.com
Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company that provides biotech and small- to mid-sized pharma companies an accelerated path to market since 1997. With a global footprint spanning 30+ offices across the Asia-Pacific region, North America, and Europe, and partnerships with 5,000+ trial sites, Novotech offers unparalleled access to key clinical trial destinations and diverse patient populations.
Novotech leverages its therapeutic and regulatory expertise, client-centric service model, local market insights, and advanced analytical tools to expedite patient recruitment, enhance trial efficiencies, and bring life-changing therapies to market faster. This work has been recognized by awards such as the Frost & Sullivan CRO Company of the Year, which Novotech has received for 19 consecutive years.
For more information or to speak to an expert team member visit: https://novotech-cro.com/talk-to-an-expert